Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 442.95 DKK -0.75% Market Closed
Market Cap: 2T DKK
Have any thoughts about
Novo Nordisk A/S?
Write Note

Relative Value

The Relative Value of one NOVO B stock under the Base Case scenario is 696.16 DKK. Compared to the current market price of 442.95 DKK, Novo Nordisk A/S is Undervalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOVO B Relative Value
Base Case
696.16 DKK
Undervaluation 36%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
74
vs Industry
18
Median 3Y
10.9
Median 5Y
9.9
Industry
2.4
Forward
5.7
vs History
80
vs Industry
21
Median 3Y
34.9
Median 5Y
29.4
Industry
21
Forward
16.3
vs History
77
vs Industry
23
Median 3Y
25.1
Median 5Y
23.1
Industry
16.2
vs History
96
vs Industry
24
Median 3Y
32.9
Median 5Y
24.5
Industry
24
vs History
82
vs Industry
3
Median 3Y
24.2
Median 5Y
20.2
Industry
2
vs History
74
vs Industry
16
Median 3Y
11
Median 5Y
9.9
Industry
2.6
Forward
5.9
vs History
74
vs Industry
22
Median 3Y
13.1
Median 5Y
11.9
Industry
5.1
vs History
87
vs Industry
25
Median 3Y
23.3
Median 5Y
21.4
Industry
12.6
Forward
12
vs History
80
vs Industry
25
Median 3Y
25.6
Median 5Y
23.4
Industry
16
Forward
12.7
vs History
74
vs Industry
23
Median 3Y
25
Median 5Y
23.1
Industry
14.4
vs History
50
vs Industry
15
Median 3Y
33.1
Median 5Y
29.7
Industry
17.6
vs History
96
vs Industry
13
Median 3Y
9.6
Median 5Y
8.7
Industry
1.8

Multiples Across Competitors

NOVO B Competitors Multiples
Novo Nordisk A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.6
US
Eli Lilly and Co
NYSE:LLY
676.4B USD 13.8 60.9 32.8 35.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
367.9B USD 4.1 16.9 12.3 16.2
CH
Roche Holding AG
SIX:ROG
206.7B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
181.7B CHF 4.1 17.1 10.1 13.5
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4 28.2 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
195.2B USD 3.1 11.2 8.4 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
132.6B USD 2.1 16.8 7.3 10.2
FR
Sanofi SA
PAR:SAN
115.5B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
DK
Novo Nordisk A/S
CSE:NOVO B
Average P/E: 22.7
19.5
18%
1.1
US
Eli Lilly and Co
NYSE:LLY
60.9
50%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.9
27%
0.6
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
17.1
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.2
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.8
30%
0.6
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
CSE:NOVO B
Average EV/EBITDA: 394.2
12.9
13%
1
US
Eli Lilly and Co
NYSE:LLY
32.8
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.1
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.4
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6
FR
Sanofi SA
PAR:SAN
5
7%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
CSE:NOVO B
Average EV/EBIT: 1 697.5
14.6
14%
1
US
Eli Lilly and Co
NYSE:LLY
35.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.5
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4